Why the study?
Does CD41-CD61 expression in circulating small extracellular vesicles reflect CMR-assessed ischemic damage in STEMI patients?
Does CD41-CD61 expression in circulating small extracellular vesicles reflect CMR-assessed ischemic damage in STEMI patients?
CD41-CD61 expression in circulating small extracellular vesicles reflects CMR-assessed ischemic damage after STEMI, potentially aiding in the timely identification of high-risk patients.
Answers are grounded in this paper and cite their sources.
sEV markers may aid early MVO risk stratification in STEMI; hypothesis-generating and requires prospective validation before clinical use.
= 0.039). sEV size and CD41-CD61 expression were independent predictors of MVO/MSI (OR [95% CI]: 0.93 [0.87-0.98] and 0.04 [0-0.61], respectively). In conclusion, we provide evidence that the CD41-CD61 expression in sEVs reflects the CMR-assessed ischemic damage after STEMI. This finding paves the way for the development of a new strategy for the timely identification of high-risk patients and their treatment optimization.
No takes yet. Share an insight, caveat, or question.
Zara et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: